Imunofan
- Category
- Bioregulators
- Administration routes
- InjectableNasal
- Regulatory status
- Not FDA-approved
What it is
A synthetic hexapeptide marketed as an immune modulator for infection recovery and immune balance. Only immune normalization has moderate support; tissue repair, vaccine adjuvant use, epigenetic effects, and anti-tumor support are speculative, mechanism-only, and barely studied in humans. Safety evidence remains limited. Russian labeling lists individual intolerance and possible temporary exacerbation of chronic inflammatory foci. Not FDA-approved, and products sold online are unregulated.
Read Full recordStudied uses & evidence
Studied uses(5)
Immunomodulatory activity (immune system normalization)
MediumMultiple human studies, including one randomized trial, show immune parameter improvements.
Skin cell proliferation and tissue repair promotion
SpeculativeSingle 2020 study: boosted skin cell growth and wound closure in mice, no human data.
Vaccine adjuvant activity
SpeculativeSingle 2025 mouse study suggests adjuvant effect against one bacterial antigen, unreplicated.
Evidence limits
- Evidence Level
- Moderate Evidence (registered drug with published studies in international journals)
Imunofan has the strongest evidence profile among Khavinson-associated peptides. It has a defined molecular structure enabling rigorous study, a 2020 MDPI publication with detailed in vitro and in vivo data, a 2025 adjuvant study, and decades of Russian clinical use as a registered pharmaceutical. The MDPI study provides Western-accessible peer-reviewed data on mechanism and efficacy. Russian clinical trials have enrolled thousands of patients across multiple indications.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Children under 2 under Russian nasal-spray labeling
AbsoluteThe Russian label permits use in older children; this does not establish FDA approval or comprehensive pediatric safety.
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(3)
Risks = level of concern: High · Moderate · Low · Theoretical
Allergic reaction
LowPotential immune modulation in autoimmune conditions
TheoreticalInjection site reactions (injectable form)
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.